Challenges and opportunies with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

Hagit Eldar-Finkelman, Ronit Ilouz

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations

Abstract

The role of the serine/threonine protein kinase, glycogen synthase kinase-3 (GSK-3), in attenuating the insulin signalling pathway has led to the concept that inhibition of GSK-3 may have therapeutic benefits in the treatment of insulin resistance and Type 2 diabetes. Indeed, various selective GSK-3 inhibitors have been developed recently and have proven to promote insulin-like effects and to act as insulin sensitisers in both in vitro and in vivo systems. GSK-3 inhibition may thus present a new, effective approach for the treatment of insulin resistance and Type 2 diabetes. This review describes the qualifications of GSK-3 as a novel drug-discovery target for Type 2 diabetes and discusses the strategies and challenges in developing small-molecule inhibitors for this important protein kinase.

Original languageEnglish
Pages (from-to)1511-1519
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume12
Issue number9
DOIs
StatePublished - 1 Sep 2003
Externally publishedYes

Keywords

  • GSK-3
  • Insulin resistance
  • Protein kinase inhibitors
  • Type 2 diabetes

Fingerprint

Dive into the research topics of 'Challenges and opportunies with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment'. Together they form a unique fingerprint.

Cite this